Skip to content

US · TIL · BIOTECHNOLOGY

Instil Bio, Inc. (TIL) intrinsic value and stock valuation

$5.23as of 2026-11-21 · Mkt cap 50.25M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Instil Bio, Inc. DCF and intrinsic value

InvestorsCraft values TIL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TIL’s statements →

Instil Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dallas, TX 75219 instilbio.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-71.37M
20192025
Free cash flow
-$-36.62M
20192025
Total equity
$113.9M-17.2% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-52.91M-$-73.54M-$-159.17M-$-206.17M-$-155.56M
Net income-$-71.37M-$-74.14M-$-156.09M-$-223.18M-$-156.79M
EPSd-$-10.7M-$-11.39M-$-24.01M-$-34.44M-$-29.58M
Operating cash flow-$-36.62M-$-55.7M-$-82.03M-$-180.16M-$-122.14M
Capital expenditure$0.00-$-10M-$-20.66M-$-84.59M-$-57.83M
Free cash flow-$-36.62M-$-65.7M-$-102.69M-$-264.75M-$-179.97M
Total assets$203.5M$263.6M$325.6M$482.1M$610M
Total debt$85.2M$86.9M$86.1M$79.9M$0.00
Net debt$78.5M$78.1M$76.9M$36.2M-$-37.59M
Total equity$113.9M$169.4M$225.8M$363.6M$555.2M
Cash and short-term investments$76.1M$113.3M$150.4M$260.9M$454.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$530K$0.00$0.00$5.99M$0.00
Gross profit-$-530K$0.00$0.00-$-5.99M$0.00
Research and development expenses$10M$11.8M$39.6M$141.1M$107.3M
Selling, general and administrative expenses$27.2M$44.2M$47.6M$62.2M$51.3M
Other expenses$15.2M$17.5M$72M-$-3.11M-$-3M
Operating expenses$52.4M$73.5M$159.2M$200.2M$155.6M
Cost and expenses$52.9M$73.5M$159.2M$206.2M$155.6M
Interest income$3.86M$6.99M$8.87M$3.65M$80K
Interest expense$5.83M$8.99M$5.21M$1.88M$0.00
Depreciation and amortization$530K$3.61M$4.76M$5.99M$2.75M
Ebitda-$-65.01M-$-62.53M-$-147.12M-$-217.38M-$-152.51M
Operating income-$-52.91M-$-73.54M-$-159.17M-$-206.17M-$-155.56M
Total other income/expenses, net-$-18.46M-$-590K$3.08M-$-19.08M-$-1.2M
Income before tax-$-71.37M-$-74.14M-$-156.09M-$-225.25M-$-156.75M
Income tax expense$0.00$0.00$0.00-$-2.07M$40K
Net income-$-71.37M-$-74.14M-$-156.09M-$-223.18M-$-156.79M
Weighted average shares outstanding$6.67M$6.51M$6.5M$6.48M$5.3M
Weighted average diluted shares outstanding$6.67M$6.51M$6.5M$6.48M$5.3M
Balance sheet
20252024202320222021
Cash and short-term investments$76.1M$113.3M$150.4M$260.9M$454.1M
Net receivables$850K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$191.4M$124.5M$160.8M$269.4M$464M
Property, plant and equipment, net$360K$130.3M$141.1M$209.3M$122M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$15.8M
Long-term investments$0.00$0.00$23.2M$0.00$0.00
Total non-current assets$12.1M$139.1M$164.9M$212.8M$146M
Total assets$203.5M$263.6M$325.6M$482.1M$610M
Accounts payable$780K$660K$1.21M$2.36M$5.57M
Short-term debt$370K$1.68M$1.75M$2.38M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.84M$7.9M$10.6M$32.8M$41.4M
Long-term debt$84.8M$85.2M$84.3M$77.5M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$84.8M$86.2M$89.2M$85.7M$13.4M
Capital lease obligations$370K$2.7M$4.63M$7.55M$0.00
Total liabilities$89.7M$94.1M$99.8M$118.5M$54.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-726.49M-$-655.12M-$-580.98M-$-424.89M-$-201.72M
Accumulated other comprehensive income (loss)-$-580K-$-230K-$-350K-$-490K-$-90K
Total equity$113.9M$169.4M$225.8M$363.6M$555.2M
Total investments$69.5M$104.5M$164.3M$217.2M$416.5M
Total debt$85.2M$86.9M$86.1M$79.9M$0.00
Net debt$78.5M$78.1M$76.9M$36.2M-$-37.59M
Cash flow statement
20252024202320222021
Net income-$-71.37M-$-74.14M-$-156.09M-$-223.18M-$-156.79M
Depreciation and amortization$530K$3.61M$4.76M$5.99M$2.75M
Stock-based compensation$8.69M$17.3M$18.2M$30.4M$26.2M
Change in working capital-$-560K-$-12.61M-$-9.02M-$-9.57M$4.36M
Accounts receivable-$-3.4M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$120K-$-560K-$-1.13M-$-1.81M$3.86M
Net cash provided by operating activities-$-36.62M-$-55.7M-$-82.03M-$-180.16M-$-122.14M
Investments in property, plant and equipment-$-10M-$-10M-$-20.66M-$-84.59M-$-57.83M
Acquisitions, net$430K$0.00$0.00$1.17M$0.00
Net cash used for investing activities$25.5M$54M$41.1M$114.5M-$-474.4M
Common stock issued$850K$0.00$0.00$1.55M$339M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.29M$1.75M$8.08M$71.9M$393.2M
Net change in cash-$-3.83M-$-60K-$-33.02M$5.63M-$-203.67M
Cash at end of period$6.8M$10.6M$10.7M$43.7M$38.1M
Operating cash flow-$-36.62M-$-55.7M-$-82.03M-$-180.16M-$-122.14M
Capital expenditure$0.00-$-10M-$-20.66M-$-84.59M-$-57.83M
Free cash flow-$-36.62M-$-65.7M-$-102.69M-$-264.75M-$-179.97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Instil Bio, Inc.

        Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.

        CEO
        Bronson Crouch
        Employees
        17
        Beta
        1.91

        Explore

        Frequently asked questions

        What is the intrinsic value of Instil Bio, Inc. (TIL)?

        InvestorsCraft does not currently publish an intrinsic value for TIL. How the IC value is calculated.

        Is TIL undervalued?

        InvestorsCraft does not publish an undervaluation signal for TIL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.